

**UNIVERSITY OF
LEADING
THE WAY
WESTMINSTER** 

WestminsterResearch

<http://www.westminster.ac.uk/research/westminsterresearch>

Array comparative genomic hybridization screening in IVF significantly reduces number of embryos available for cryopreservation

**Jiaen Liu¹, E Scott Sills^{2*}, Zhihong Yang², Shala A Salem²,
Tayyab Rahil², Gary S Collins³, Xiaohong Liu¹, Rifaat D Salem²**

¹ IVF Division, Beijing Jia En De Yun Hospital, Beijing, China

² Division of Reproductive Endocrinology, Pacific Reproductive Center, Torrance, USA

³ Centre for Statistics in Medicine, Wolfson College Annexe, University of Oxford, Oxford, UK

* E Scott Sills now works within the Graduate School of Life Sciences, University of Westminster, London, UK

This is a copy of the final published version of an article that appeared in *Clinical & Experimental Reproductive Medicine*, 39 (2). pp. 52-57, 2012. It is available online at:

<http://dx.doi.org/10.5653/cerm.2012.39.2.52>

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/3.0/>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

The WestminsterResearch online digital archive at the University of Westminster aims to make the research output of the University available to a wider audience. Copyright and Moral Rights remain with the authors and/or copyright owners.

Whilst further distribution of specific materials from within this archive is forbidden, you may freely distribute the URL of WestminsterResearch: (<http://westminsterresearch.wmin.ac.uk/>).

In case of abuse or copyright appearing without permission e-mail repository@westminster.ac.uk

Array comparative genomic hybridization screening in IVF significantly reduces number of embryos available for cryopreservation

Jiaen Liu¹, E Scott Sills², Zhihong Yang², Shala A Salem², Tayyab Rahil², Gary S Collins³, Xiaohong Liu¹, Rifaat D Salem²

¹IVF Division, Beijing Jia En De Yun Hospital, Beijing, China; ²Division of Reproductive Endocrinology, Pacific Reproductive Center, Torrance, USA;

³Centre for Statistics in Medicine, Wolfson College Annexe, University of Oxford, Oxford, UK

Objective: During IVF, non-transferred embryos are usually selected for cryopreservation on the basis of morphological criteria. This investigation evaluated an application for array comparative genomic hybridization (aCGH) in assessment of surplus embryos prior to cryopreservation.

Methods: First-time IVF patients undergoing elective single embryo transfer and having at least one extra non-transferred embryo suitable for cryopreservation were offered enrollment in the study. Patients were randomized into two groups: Patients in group A (n = 55) had embryos assessed first by morphology and then by aCGH, performed on cells obtained from trophoctoderm biopsy on post-fertilization day 5. Only euploid embryos were designated for cryopreservation. Patients in group B (n = 48) had embryos assessed by morphology alone, with only good morphology embryos considered suitable for cryopreservation.

Results: Among biopsied embryos in group A (n = 425), euploidy was confirmed in 226 (53.1%). After fresh single embryo transfer, 64 (28.3%) surplus euploid embryos were cryopreserved for 51 patients (92.7%). In group B, 389 good morphology blastocysts were identified and a single top quality blastocyst was selected for fresh transfer. All group B patients (48/48) had at least one blastocyst remaining for cryopreservation. A total of 157 (40.4%) blastocysts were frozen in this group, a significantly larger proportion than was cryopreserved in group A ($p = 0.017$, by chi-squared analysis).

Conclusion: While aCGH and subsequent frozen embryo transfer are currently used to screen embryos, this is the first investigation to quantify the impact of aCGH specifically on embryo cryopreservation. Incorporation of aCGH screening significantly reduced the total number of cryopreserved blastocysts compared to when suitability for freezing was determined by morphology only. IVF patients should be counseled that the benefits of aCGH screening will likely come at the cost of sharply limiting the number of surplus embryos available for cryopreservation.

Keywords: Fertilization *in vitro*; Comparative genomic hybridization; Preimplantation genetic diagnosis; Cryopreservation

Introduction

Within the arena of assisted reproduction, several technologies have emerged to address the most important challenge in human fertility

Received: Apr 21, 2012 · Revised: May 9, 2012 · Accepted: May 14, 2012

Corresponding author: E Scott Sills

Division of Reproductive Endocrinology, Pacific Reproductive Center (PRC-Fertility); Irvine, California 92618, USA

Tel: +1-949-341-0100 Fax: +1-949-341-0613 E-mail: dr.sills@prc-ivf.com

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/3.0/>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

medicine: multiple gestation. Single embryo transfer, either elective or mandatory, has been proposed as a way to avoid this problem [1-4]. Selection of an embryo for transfer or cryopreservation is typically done on the basis of morphology [5,6]. However, since suitable morphology by itself cannot negate the potential for chromosomal error in the selected embryo, the transfer or cryopreservation of apparently "normal looking" embryo carries considerable risk [7]. Experience with IVF has shown that aneuploidy is the most common abnormality in human embryos [8-15] and this characteristic contributes substantially to poor reproductive outcomes observed in advanced fertility treatments [16]. As other investigators have noted [17-21], screen-

ing embryos by fluorescence in situ hybridization was a reasonable first answer to this challenge, but the approach was too limited because it could not screen all chromosomes at the same time. More recently, single nucleotide polymorphism array and array comparative genomic hybridization (aCGH) have been used to achieve comprehensive chromosome screening to improve efficiency of embryo transfer [22-30]. These techniques enable subsequent frozen embryo transfer so that only euploid embryo(s) are used therapeutically, thus improving implantation and reducing risk of miscarriage. However, because experience using these molecular cytogenetic tests in reproductive medicine remains limited, there is a critical need to validate embryo selection techniques before such technology enters the clinical mainstream [31]. Yet while the optimal method of determining the chromosomal composition of the human embryo remains unsettled, there has been little or no discussion specifically focused on how such technologies might affect the total number of embryos available for cryopreservation. Accordingly, this study compared the impact of aCGH on cryopreservation yield when this molecular cytogenetic technique was applied to young, low-risk patients undergoing their first IVF cycle.

Methods

1. Patient sample

To study the impact of aCGH on embryo cryopreservation rate in IVF, patients at our clinics in Los Angeles and Beijing were offered enrollment in this prospective, single-blind investigation. Institutional Review Board approval was obtained before recruitment and written informed consent was obtained from all study participants. All patients received pre-treatment counseling about aCGH and how this testing technique might affect the number of embryos cryopreserved. Patients were eligible for this study if (female) age was < 35 years, if there was a history of regular ovulation, if etiology of infertility was tubal factor or male factor (or both), and if no prior IVF treatment had been initiated. Additionally, all study subjects were required to have a normal 46,XX karyotype, two ovaries, a normal endometrial contour, and basal serum FSH and estradiol on d2-3 at < 10 IU/L and < 60 pg/mL, respectively. IVF patients whose treatment incorporated donor gametes or frozen/thawed embryos were excluded. A random number table was used to determine patients embryo cryopreservation protocol as either 1) traditional morphology assessment plus aCGH (group A, n=55), or 2) conventional morphology assessment only (group B, n=48). Patients (but not laboratory or clinical staff) were blinded with regard to their randomization group, and clinical features of the two study groups were similar. The two cohorts were mutually exclusive; no study patient had embryos assigned to both laboratory groups.

2. Ovarian stimulation and fertilization

Baseline transvaginal ultrasound evaluation was performed before starting ovulation induction medications, with re-measurement of serum FSH, LH and estradiol on d3 of the index cycle. GnRH-agonist administered on d21 of the cycle immediately preceding treatment was used to attain pituitary downregulation, as described previously [32]. Periodic transvaginal ultrasound and serum estradiol measurements were used to monitor follicular growth and thickness of endometrial lining. When ≥ 3 follicles reached 19 mm mean diameter, periovulatory hCG was administered by subcutaneous injection of recombinant hCG (250 μ g Ovidrel, Merck Serono, Geneva, Switzerland) with oocyte retrieval performed under transvaginal ultrasound guidance 35-36 hours later. Following removal of all cumulus cells, ICSI was performed with a 30° needle, and normal fertilization was verified 16-18 hours after injection by presence of two pronuclei and two polar bodies.

3. Embryo culture and trophectoderm biopsy

Sequential media (Vitrolife, Göteborg, Sweden) was used to support all embryos to blastocyst stage. On d3 when embryos were at the 6-8 cell stage, a noncontact 1.48 μ m diode laser (OCTAX Microscience GmbH, Bruckberg, Germany) was used to create a circular 6-9 μ m diameter opening in the zona pellucida (ZP). For embryos randomized to the aCGH group, this lacuna facilitated biopsy of trophectoderm (TE) on d5. Between 3-5 herniated TE cells were gently aspirated by pipette and, when necessary, freed from the blastocyst by application of several laser pulses. Harvested TE cells were washed in phosphate buffered solution (PBS) and placed within a polymerase chain reaction tube with 2.5 μ L 1 \times PBS as previously described [33]. The same assisted hatching protocol was used for all embryos irrespective of subsequent TE biopsy or conventional microscopic assessment alone.

4. aCGH protocol

The SurePlex DNA amplification system (BlueGnome Ltd., Cambridge, UK) was used on-site for whole genome amplification in accordance with manufacturer's guidelines [33,34]. Briefly, samples and control DNA (8 μ L for each) were labeled with Cy3 and Cy5 fluorophores (BlueGnome Ltd.). Labeling time was approximately 3 hours with DNA resuspended in dextran sulphate hybridization buffer and hybridized overnight under cover slides. After washing 1 \times 10 minutes in saline sodium citrate (SSC)/0.05% Tween-20 at room temperature, an additional irrigation in SSC 1 \times 10 minutes was completed at room temperature. Slides were washed in SSC 1 \times 5 minutes at 60°C and again for 1 minute at room temperature (in SSC). Vacuum centrifuge was used to dry microarray slides over 3 minutes, followed by laser scanning at 10 μ m (Agilent Technologies, Santa Clara, CA, USA). Blue-

Fuse software (BlueGnome, Ltd.) was used for analysis of microarray data on chromatin loss/gain across all 24 chromosomes. Aberrations were considered non-artifact if ≥ 15 probes deviated from normal limits as defined by the 24 sure platform. The published accuracy rate for this aCGH technique when applied to TE cells is 95% [34].

5. Selection criteria for cryopreservation

In both aCGH and control groups, blastocysts were graded [35] on a 1 to 6 scale determined by degree of expansion and hatching status, as follows: grade 1 (early blastocyst): blastocoele < 1/2 of total embryo volume; grade 2 (intermediate blastocyst): blastocoele $\geq 1/2$ of total embryo volume; grade 3 (full blastocyst): blastocoele fully occupies the embryo; grade 4 (expanded blastocyst): blastocoele is larger than early blastocyst and ZP demonstrates thinning; grade 5 (hatching blastocyst): herniation of TE cells from the ZP; and grade 6 (hatched blastocyst): blastocyst has escaped the ZP. For blastocysts at grades 3 to 6, the inner cell mass (ICM) and TE were also graded. The ICM was graded as follows: A (many ICM cells packed together tightly); B (several ICM cells grouped loosely) and C (very few ICM cells). TE was graded as follows: A (numerous TE cells forming multiple epithelial layers); B (few TE cells consisting of a loose epithelium) and C (scarce large TE cells). For embryos in the aCGH group only one euploid blastocyst was selected for transfer based on aCGH data and surplus euploid blastocysts were vitrified for later use [35]. In the non-aCGH (control) group, a single blastocyst was selected for fresh transfer based on morphological criteria only (i.e., no aCGH evaluation) and those blastocysts with good morphology (grade 3BB or above) were vitrified the same day.

6. Outcome measures and statistical analysis

The number of cryopreserved blastocysts was recorded and compared for IVF patients where aCGH was utilized and for those where cryopreservation was determined by morphology alone. Differences between groups were assessed by chi-square test. A difference of $p < 0.05$ was considered statistically significant.

Results

A total of 188 IVF patients met inclusion criteria and 112 volunteered for enrollment (59.6%) during the four-month investigation. Of 56 patients randomized to each group, some did not initiate IVF due to failure to complete required pre-IVF testing, they postponed treatment until a later date, or for other reasons. For group A (morphology + aCGH) and group B (morphology only) 55 and 48 IVF patients completed the study, respectively. There were no cancellations or complications for any patient in either study group.

For patients in group A, 425 of 457 blastocysts were biopsied and

analyzed via aCGH (7.7 blastocysts/patient). Trophectoderm biopsy could not be completed in 7% of blastocysts (n = 32) due to indistinct TE (poor morphology) or because they degenerated after biopsy. This evaluation revealed aneuploidy in 191/425 (44.9%) of blastocysts. 'No signal' due to amplification failure occurred in 8 blastocysts. Among aneuploid blastocysts, 68/191 (35.6%) had single chromosome loss (monosomy) and 20.9% displayed single chromosome gain (trisomy). Approximately 43% of aneuploid blastocysts were chromosomally abnormal due to a severe, compound genetic defect where two or more chromosomes were affected. While chromosomal abnormalities were detected in all chromosomes, disruptions involving chromosomes 15, 16, 21, 22, and X were most frequently observed. Errors of chromosomes 4 and 6 were relatively uncommon. All patients in group A had at least one euploid blastocyst available for transfer on d6. For patients in group B, 389 blastocysts were microscopically examined (8.1 blastocysts/patient).

Among biopsied embryos in group A (n = 425), euploidy was confirmed in 226 (53.1%). After fresh single embryo transfer, 64 (28.3%) surplus euploid embryos were cryopreserved for 51 study patients (92.7% of patients in this group). In group B, 389 good morphology blastocysts were identified and a single top quality blastocyst was selected for fresh transfer. As shown in Table 1, the cryopreservation yield for group B patients was 100% (48/48), because patients in this group all had at least one blastocyst remaining for cryopreservation. A total of 157 (40.4%) blastocysts were frozen in this group, a significantly larger proportion than was cryopreserved in group A ($p = 0.017$, by chi-squared analysis).

Discussion

Although the role of embryo cryopreservation will doubtless hold its essential niche in the modern IVF unit, it is not yet known exactly

Table 1. Summary of IVF study patient data for blastocyst cryopreservation following conventional morphology assessment plus comprehensive chromosomal screening via array CGH (group A), or conventional morphology assessment only (group B)

Parameters	A	B
Patients enrolled	55	48
Patients with cryopreserved blastocysts	51	48
Blastocysts available for bx	457	n/a
Bx completed	425	n/a
Euploid blastocysts	226	n/a
Blastocysts remaining after ET	171	341
Cryopreserved blastocysts ^a	64	157

Demographic and clinical parameters were similar for both randomized groups. CGH, comparative genomic hybridization; Bx, biopsy; n/a, not applicable; ET, embryo transfer.

^aA vs. B, $p = 0.017$ (by chi-square test).

how newer molecular testing techniques will affect this aspect of assisted fertility treatment. As more practice jurisdictions move toward a mandatory single embryo transfer policy, it may be that pre-transfer assessment of embryos by aCGH (or some other screening method) will become a regular procedure in IVF. Should fresh transfers be limited only to single embryos which undergo routine chromosomal screening, then the number of surplus cryopreserved embryos may be expected to rise. But thus far, clinical research has focused on application of comprehensive chromosomal screening specifically for patients with known translocation, multiple implantation failure or recurrent pregnancy loss [7,19,29]. To our knowledge, a prospective study of cryopreservation yield following aCGH screening of embryos from IVF patients without such history (i.e., first cycle IVF, age < 35 and good prognosis) has not yet been conducted. The present investigation was undertaken to address this gap in the literature by providing measurements on rate of blastocyst cryopreservation as a function of aCGH inputs in this setting.

Among young patients with normal karyotype undertaking their first IVF cycle, with no miscarriage history or other predictors of poor prognosis, the present study found euploidy in only 226 of 425 blastocysts (53.1%) as determined by aCGH testing. Although most (92.7%) patients in this group had at least one euploid blastocyst for cryopreservation after fresh transfers, just 67 blastocysts remained for cryopreservation in this group (29.6%). When embryo cryopreservation was performed on the basis of standard morphology assessment alone, all study 48 patients had at least one blastocyst available for cryopreservation. For this group, a total of 154 (39.6%) blastocysts were frozen. Since all study patients were < 35 years of age, a very good chance to achieve surplus blastocysts for cryopreservation was expected regardless of randomization group (100% vs. 92.7%). However, a significantly lower ($p=0.017$) proportion of surplus blastocysts were available for cryopreservation when aCGH testing was performed (39.6% vs. 29.6%). Interestingly, when cryopreservation yield is calculated on the basis of blastocysts remaining after fresh transfers rather than absolute (total) number of blastocysts, this difference between study groups persists. Such findings underscore the need for careful counseling for IVF patients throughout the treatment sequence, particularly as the critical time for embryo cryopreservation nears [36,37].

Our work extends prior observations to younger, lower-risk IVF population and finds conventional morphological criteria alone to be insufficiently accurate to select blastocysts for cryopreservation. Focusing on a good-prognosis IVF patient population, the current study provides further evidence of substantial genetic abnormality (including monosomy and complex aneuploidy [7,25,38]) in apparently normal blastocysts which otherwise would have been destined for cryostorage. We believe IVF patients should be counseled that the

benefits of aCGH screening are likely to come at the cost of sharply limiting the number of surplus embryos available for cryopreservation. While we favor use of comprehensive chromosomal screening during IVF, these data place the shortcomings of standard embryo morphology –even for good prognosis IVF patients– in sharp relief. From this background an important clinical question emerges: If aCGH were to be become routinely integrated into the IVF treatment sequence, then what is the expected impact on the number of embryos available for cryopreservation?

Several limitations of our investigation should be acknowledged. Because blastocysts in our control group were selected by morphology alone, they were cryopreserved without any genetic testing and therefore have an uncertain reproductive potential. This study was not designed to measure reproductive outcomes after thaw and transfer. Additionally, we were not confident to include a power analysis prior to this investigation because the actual incidence of embryo aneuploidy in first-time IVF patients with no risk factors is unknown (i.e., if no significant difference had been identified, type II error could not have been excluded).

A changing public perception of better prognosis from IVF specifically when frozen embryos are thawed and transferred [39] has further increased general awareness of cryopreservation's central role in the advanced reproductive technologies [38,40,41]. Moreover, recent advancements in whole genome amplification and comprehensive chromosomal screening have permitted levels of human embryo surveillance that were not possible only a few years ago. These developments offer opportunities to verify an embryo's genetic composition before cryopreservation. The present study suggests that designating an embryo for freezing without the benefit of information gained from aCGH would entail the preservation and storage of a reproductively incompetent –albeit morphologically normal– embryo. A multi-center randomized clinical trial with a larger sample will be helpful to validate these preliminary findings.

Conflict of interest

No potential conflict of interest relevant to this article was reported.

References

1. Coetsier T, Dhont M. Avoiding multiple pregnancies in *in-vitro* fertilization: who's afraid of single embryo transfer? *Hum Reprod* 1998;13:2663-4.
2. Ryan GL, Sparks AE, Sipe CS, Syrop CH, Dokras A, Van Voorhis BJ. A mandatory single blastocyst transfer policy with educational campaign in a United States IVF program reduces multiple ges-

- tation rates without sacrificing pregnancy rates. *Fertil Steril* 2007; 88:354-60.
3. Zander-Fox DL, Tremellen K, Lane M. Single blastocyst embryo transfer maintains comparable pregnancy rates to double cleavage-stage embryo transfer but results in healthier pregnancy outcomes. *Aust N Z J Obstet Gynaecol* 2011;51:406-10.
 4. Maheshwari A, Griffiths S, Bhattacharya S. Global variations in the uptake of single embryo transfer. *Hum Reprod Update* 2011; 17:107-20.
 5. Gardner DK, Surrey E, Minjarez D, Leitz A, Stevens J, Schoolcraft WB. Single blastocyst transfer: a prospective randomized trial. *Fertil Steril* 2004;81:551-5.
 6. Racowsky C, Ohno-Machado L, Kim J, Biggers JD. Is there an advantage in scoring early embryos on more than one day? *Hum Reprod* 2009;24:2104-13.
 7. Alfarawati S, Fragouli E, Colls P, Stevens J, Gutiérrez-Mateo C, Schoolcraft WB, et al. The relationship between blastocyst morphology, chromosomal abnormality, and embryo gender. *Fertil Steril* 2011;95:520-4.
 8. Hassold T, Hunt P. Maternal age and chromosomally abnormal pregnancies: what we know and what we wish we knew. *Curr Opin Pediatr* 2009;21:703-8.
 9. Kuliev A, Cieslak J, Verlinsky Y. Frequency and distribution of chromosome abnormalities in human oocytes. *Cytogenet Genome Res* 2005;111:193-8.
 10. Bielanska M, Tan SL, Ao A. Chromosomal mosaicism throughout human preimplantation development in vitro: incidence, type, and relevance to embryo outcome. *Hum Reprod* 2002;17:413-9.
 11. Magli MC, Gianaroli L, Ferraretti AP, Lappi M, Ruberti A, Farfalli V. Embryo morphology and development are dependent on the chromosomal complement. *Fertil Steril* 2007;87:534-41.
 12. Munné S, Alikani M, Tomkin G, Grifo J, Cohen J. Embryo morphology, developmental rates, and maternal age are correlated with chromosome abnormalities. *Fertil Steril* 1995;64:382-91.
 13. Munné S, Sandalinas M, Magli C, Gianaroli L, Cohen J, Warburton D. Increased rate of aneuploid embryos in young women with previous aneuploid conceptions. *Prenat Diagn* 2004;24:638-43.
 14. Munné S, Chen S, Colls P, Garrisi J, Zheng X, Cekleniak N, et al. Maternal age, morphology, development and chromosome abnormalities in over 6000 cleavage-stage embryos. *Reprod Biomed Online* 2007;14:628-34.
 15. Vanneste E, Voet T, Le Caignec C, Ampe M, Konings P, Melotte C, et al. Chromosome instability is common in human cleavage-stage embryos. *Nat Med* 2009;15:577-83.
 16. Wilton L. Preimplantation genetic diagnosis and chromosome analysis of blastomeres using comparative genomic hybridization. *Hum Reprod Update* 2005;11:33-41.
 17. Staessen C, Platteau P, Van Assche E, Michiels A, Tournaye H, Camus M, et al. Comparison of blastocyst transfer with or without preimplantation genetic diagnosis for aneuploidy screening in couples with advanced maternal age: a prospective randomized controlled trial. *Hum Reprod* 2004;19:2849-58.
 18. Hardarson T, Hanson C, Lundin K, Hillensjo T, Nilsson L, Stevic J, et al. Preimplantation genetic screening in women of advanced maternal age caused a decrease in clinical pregnancy rate: a randomized controlled trial. *Hum Reprod* 2008;23:2806-12.
 19. Schoolcraft WB, Katz-Jaffe MG, Stevens J, Rawlins M, Munne S. Preimplantation aneuploidy testing for infertile patients of advanced maternal age: a randomized prospective trial. *Fertil Steril* 2009;92:157-62.
 20. Mastenbroek S, Twisk M, van Echten-Arends J, Sikkema-Raddatz B, Korevaar JC, Verhoeve HR, et al. In vitro fertilization with preimplantation genetic screening. *N Engl J Med* 2007;357:9-17.
 21. Mastenbroek S, Twisk M, van der Veen F, Repping S. Preimplantation genetic screening: a systematic review and meta-analysis of RCTs. *Hum Reprod Update* 2011;17:454-66.
 22. Voullaire L, Wilton L, Slater H, Williamson R. Detection of aneuploidy in single cells using comparative genomic hybridization. *Prenat Diagn* 1999;19:846-51.
 23. Wells D, Delhanty JD. Comprehensive chromosomal analysis of human preimplantation embryos using whole genome amplification and single cell comparative genomic hybridization. *Mol Hum Reprod* 2000;6:1055-62.
 24. Sher G, Keskindepe L, Keskindepe M, Ginsburg M, Maassarani G, Yakut T, et al. Oocyte karyotyping by comparative genomic hybridization (correction of hybridization) provides a highly reliable method for selecting "competent" embryos, markedly improving in vitro fertilization outcome: a multiphase study. *Fertil Steril* 2007;87:1033-40.
 25. Fragouli E, Lenzi M, Ross R, Katz-Jaffe M, Schoolcraft WB, Wells D. Comprehensive molecular cytogenetic analysis of the human blastocyst stage. *Hum Reprod* 2008;23:2596-608.
 26. Hellani A, Abu-Amro K, Azouri J, El-Akoum S. Successful pregnancies after application of array-comparative genomic hybridization in PGS-aneuploidy screening. *Reprod Biomed Online* 2008;17:841-7.
 27. Fishel S, Gordon A, Lynch C, Dowell K, Ndukwe G, Kelada E, et al. Live birth after polar body array comparative genomic hybridization prediction of embryo ploidy-the future of IVF? *Fertil Steril* 2010;93:1006.e7- e10.
 28. Gutiérrez-Mateo C, Colls P, Sánchez-García J, Escudero T, Prates R, Ketterson K, et al. Validation of microarray comparative genomic hybridization for comprehensive chromosome analysis of embryos. *Fertil Steril* 2011;95:953-8.

29. Fiorentino F, Spizzichino L, Bono S, Biricik A, Kokkali G, Rienzi L, et al. PGD for reciprocal and Robertsonian translocations using array comparative genomic hybridization. *Hum Reprod* 2011;26:1925-35.
30. Handyside AH. PGD and aneuploidy screening for 24 chromosomes by genome-wide SNP analysis: seeing the wood and the trees. *Reprod Biomed Online* 2011;23:686-91.
31. Harper JC, Sengupta SB. Preimplantation genetic diagnosis: state of the art 2011. *Hum Genet* 2012;131:175-86.
32. Sills ES, Schattman GL, Veeck LL, Liu HC, Prasad M, Rosenwaks Z. Characteristics of consecutive in vitro fertilization cycles among patients treated with follicle-stimulating hormone (FSH) and human menopausal gonadotropin versus FSH alone. *Fertil Steril* 1998;69:831-5.
33. Yang Z, Salem S, Salem-Lyle S, Bayrak A, Salem RD. Trophectoderm cells derived from blastocyst biopsy are suitable for array CGH analysis of 24 chromosomes. *Fertil Steril* 2011;95:523.
34. Alfarawati S, Fragouli E, Colls P, Wells D. First births after preimplantation genetic diagnosis of structural chromosome abnormalities using comparative genomic hybridization and microarray analysis. *Hum Reprod* 2011;26:1560-74.
35. Sakkas D, Gardner DK. Noninvasive methods to assess embryo quality. *Curr Opin Obstet Gynecol* 2005;17:283-8.
36. Ismail WA, Menezes MQ, Martin CW, Thong KJ. A comparison of psychological functioning in couples undergoing frozen-thawed embryo replacement in various stages of treatment using the Mean Affect Adjective Check List (MAACL). *J Assist Reprod Genet* 2004;21:323-7.
37. Karatas JC, Barlow-Stewart K, Meiser B, McMahon C, Strong KA, Hill W, et al. A prospective study assessing anxiety, depression and maternal-fetal attachment in women using PGD. *Hum Reprod* 2011;26:148-56.
38. Sills ES, Walsh DJ, Walsh AP. Results from the advanced reproductive technologies: fresh vs. frozen? *Ir Med J* 2008;101:288.
39. Paxman L. IVF babies born from frozen embryos are healthier than those from fresh ones. *London Daily Mail* 2012 Jan 6; A3.
40. Chang EM, Han JE, Kim YS, Lyu SW, Lee WS, Yoon TK. Use of the natural cycle and vitrification thawed blastocyst transfer results in better in-vitro fertilization outcomes : cycle regimens of vitrification thawed blastocyst transfer. *J Assist Reprod Genet* 2011;28:369-74.
41. Zhu D, Zhang J, Cao S, Heng BC, Huang M, Ling X, et al. Vitrified-warmed blastocyst transfer cycles yield higher pregnancy and implantation rates compared with fresh blastocyst transfer cycles—time for a new embryo transfer strategy? *Fertil Steril* 2011;95:1691-5.